Eesti - eesti - Ravimiamet

patheon manufacturing services llc - teklistamab - süstelahus - 90mg 1ml 1.7ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastilised ained - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Eesti - eesti - Ravimiamet

vetter pharma-fertigung gmbh & co. kg - tremelimumab - infusioonilahuse kontsentraat - 20mg 1ml 1.25ml 12tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lümfoom, follikulaarne - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Eesti - eesti - Ravimiamet

genentech inc. - glofitamab - infusioonilahuse kontsentraat - 1mg 1ml 10ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Eesti - eesti - Ravimiamet

patheon manufacturing services llc - talkuetamab - süstelahus - 2mg 1ml 1.5ml 1tk

Eesti - eesti - Ravimiamet

patheon manufacturing services llc - talkuetamab - süstelahus - 40mg 1ml 1ml 1tk

Eesti - eesti - Ravimiamet

abbvie deutschland gmbh & co. kg - epkoritamab - süstelahuse kontsentraat - 48mg 0.8ml 0.8ml 1tk